This study explores the potential of graphene oxide (GO) as an additive in waterborne polyurethane (WPU) resins to create eco-friendly coatings with enhanced anticorrosive properties. Traditionally, WPU's hydrophilic nature has limited its use in corrosion-resistant coatings. We investigate the impact of incorporating various GO concentrations (0.01, 0.1, and 1.3 wt%) and functionalizing GO with ethylenediamine (EDA) on the development of anticorrosive coatings for carbon steel. It was observed, by potentiodynamic polarization analysis in a 3.5% NaCl solution, that the low GO content in the WPU matrix significantly improved anticorrosion properties, with the 0.01 wt% GO-EDA formulation showing exceptional performance, high E (-117.82 mV), low i (3.70 × 10 A cm), and an inhibition corrosion efficiency (η) of 99.60%. Raman imaging mappings revealed that excessive GO content led to agglomeration, creating pathways for corrosive species. In UV/condensation tests, the 0.01 wt% GO-EDA coating exhibited the most promising results, with minimal corrosion products compared to pristine WPU. The large lateral dimensions of GO sheets and the cross-linking facilitated by EDA enhanced the interfacial properties and dispersion within the WPU matrix, resulting in superior barrier properties and anticorrosion performance. This advancement underscores the potential of GO-based coatings for environmentally friendly corrosion protection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11397095PMC
http://dx.doi.org/10.3390/molecules29174163DOI Listing

Publication Analysis

Top Keywords

001 wt%
12
waterborne polyurethane
8
graphene oxide
8
anticorrosion performance
8
wpu matrix
8
wt% go-eda
8
eco-friendly waterborne
4
polyurethane coating
4
coating modified
4
modified ethylenediamine-functionalized
4

Similar Publications

Objectives: To estimate tumour volume doubling time (TVDT) of interval cancers (ICs).

Methods: Two radiologists retrospectively reviewed prior screening and diagnostic mammograms and measured mean diameter on "visible" ICs. Univariate analyses of clinicopathological variables (ER, HER2, grade, age at diagnosis, and breast density) were undertaken, and those with p < 0.

View Article and Find Full Text PDF

Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact.

Eur J Cancer

January 2025

Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address:

Mismatch repair deficiency (MMR-d) and microsatellite instability (MSI) are prognostic and predictive biomarkers in oncology. Current testing for MMR/MSI relies on immunohistochemistry (IHC) for MMR proteins and molecular assays for MSI detection. This combined diagnostic strategy, however, lacks tumor specificity and does not account for gene variants.

View Article and Find Full Text PDF

We created the c.1286C>G stop-gain mutation found in a family with primary ovarian insufficiency (POI) at age 30 years. The Eif4enif1 C57/Bl6 transgenic mouse model contained a floxed exon 10-19 cassette with a conditional knock-in cassette containing the c.

View Article and Find Full Text PDF

Background: This study aimed to develop ion-releasing and antibacterial resin-based dental sealants comprising 3 to 6 wt% monocalcium phosphate monohydrate (MCPM, M), 3 to 6 wt% bioactive glass (BAG, B), and 3 to 6 wt% polylysine (PLS, P). The physical properties, mechanical performance, cytotoxicity, and inhibition of S. mutans biofilm by these materials were subsequently evaluated.

View Article and Find Full Text PDF

To assess the effectiveness and safety of Sacubitril/Valsartan in reducing blood pressure in individuals with non-dialysis-dependent chronic kidney disease (NDD-CKD) Stage 3-5 complicated by hypertension. This study was a multicenter retrospective analysis conducted from March 1, 2022 to March 31, 2024, involving adult patients with NDD-CKD Stage 3-5 and hypertension, who received Sacubitril/Valsartan either as a monotherapy or in addition to current antihypertensive treatments that were insufficient. The main outcomes measured were blood pressure control, changes in blood pressure and laboratory parameters within 8 weeks post-treatment initiation, and incidence of adverse events.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!